Clinical trial shows 15-day Paxlovid regimen safe but adds no clear benefit for long COVID

In a clinical trial conducted by Stanford Medicine investigators and their colleagues, a 15-day course of Paxlovid—an antiviral drug combination targeting SARS-CoV-2, the virus that causes COVID-19—proved safe as an extended-duration treatment but didn’t lessen select symptoms of the syndrome known as long COVID: the persistence, or reappearance, of COVID-related symptoms three months or more after an initial COVID-19 infection.

​Medical Xpress – latest medical and health news stories

Read More


Discover more from Nurse Unity Chats

Subscribe to get the latest posts sent to your email.

Comments

No comments yet. Why don’t you start the discussion?

Leave a Reply

Your email address will not be published. Required fields are marked *